Serenex Announces Initiation of Second Phase 1 Trial for Oral Hsp90 Inhibitor, SNX-5422

DURHAM, NC--(Marketwire - December 04, 2007) - Serenex, Inc., a leader in the discovery and development of small molecule Heat Shock Protein 90 (Hsp90) inhibitors, today announced the initiation of a second phase 1 trial, in hematological malignancies, for SNX-5422, its novel heat shock protein 90 (Hsp90) inhibitor. SNX-5422 is a totally synthetic small molecule delivered orally and was discovered internally using Serenex's proprietary chemoproteomics technology platform.